doi: 10.1093/labmed/16.11.653pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/16.11.659pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/16.11.660pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
Hyun, Bong, H.;Salazar, Gerardo, H.
doi: 10.1093/labmed/16.11.667pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
doi: 10.1093/labmed/16.11.671pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
Lane, James, R.;Bowles, Karen, J.;Normansell, David, E.
doi: 10.1093/labmed/16.11.676pmid: N/A
Abstract A method is described for the removal of the majority of IgG from serum in order to permit the characterization of low levels of IgM monoclonal proteins. The method involves ion exchange chromatography using a commercially available kit developed for the analysis of IgM antibody titers. The procedure is rapid, easy to perform, and economical. This content is only available as a PDF. © American Society of Clinical Pathologists
Grose,, Mary;Waller, Kathy, V.
doi: 10.1093/labmed/16.11.679pmid: N/A
Abstract Medical technologists at The Ohio State University Hospitals Clinical Laboratories participated in an aggressive program to inoculate personnel at high risk of exposure to hepatitis B virus. The immune status of the participants, determined prior to vaccination, included hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core IgG antibody tests. Of the 200 technologists found to be negative for all markers, 43 received the vaccine for hepatitis B virus, through injection in the buttocks. Antibody status was determined one month and 12 months following the third dose. Thirty two of the 43 (74%) had detectable antibody at one month, but 18 of those 32 (40%) had no detectable antibody eleven months later. Eleven of 43 (26%) never seroconverted; 14 of 43 (33%) were still positive after 12 months. This content is only available as a PDF. © American Society of Clinical Pathologists
DiRusso,, Steven;Atkinson,, Prescott;Parkinson,, Neale;Bennett,, Beth;Hunter,, Robert
doi: 10.1093/labmed/16.11.681pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
Duray, Paul, Harrison;Kusnitz,, Adele;Ryan,, John
doi: 10.1093/labmed/16.11.685pmid: N/A
Article PDF first page preview Close This content is only available as a PDF. © American Society of Clinical Pathologists
Grosjean,, Stephen;Rank, Elliot, L.
doi: 10.1093/labmed/16.11.688pmid: N/A
Abstract The identification of coagulase-negative staphylococci to the species level was achieved by adapting 12 conventional biochemical test procedures to a microtiter plate format. The tests included production of urease and phosphatase, reduction of nitrate to nitrite, and acid production from nine carbohydrates. There were separate assessments of susceptibility to novobiocin and capability for beta hemolysis. This technique yielded consistent biochemical reactions for all 33 stock strains used for quality control, although one of the strains may have been incorrectly identified. In addition, 110 of 113 clinical isolates of coagulase-negative staphylococci could be identified. This content is only available as a PDF. © American Society of Clinical Pathologists
Showing 1 to 10 of 21 Articles